Neogen Corp (NEOG) valuation
Neogen P/E ratio history
Neogen has no meaningful price to earnings ratio at the last close, which happens when earnings over the last twelve months are negative or close to zero. At its last 6 fiscal year ends its P/E ranged from 49.0 (year to May 2019) to 81.0 (year to May 2021), with a median of 60.7.
| Fiscal year ended | Price | EPS | P/E | Forward P/E |
|---|---|---|---|---|
| May 31, 2026 | $8.97 | -$0.04 | n/m | — |
| May 31, 2025 | $5.86 | -$5.03 | n/m | 12.5 |
| May 31, 2024 | $13.15 | -$0.04 | n/m | — |
| May 31, 2023 | $17.49 | -$0.12 | n/m | — |
| May 31, 2022 | $26.46 | $0.45 | 58.8 | — |
| May 31, 2021 | $46.16 | $0.57 | 81.0 | — |
| May 31, 2020 | $35.61 | $0.55 | 64.8 | — |
| May 31, 2019 | $28.18 | $0.57 | 49.0 | — |
| May 31, 2018 | $37.85 | $0.60 | 62.6 | — |
| May 31, 2017 | $23.73 | $0.43 | 55.2 | — |
n/m: not meaningful (a loss, or earnings close to zero). The daily P/E line is a chart indicator in the app.
Neogen valuation against its peers
| Company | Market value | P/E | Forward P/E | Price / sales |
|---|---|---|---|---|
| NeogenNEOG | $2.58B | — | 32.6 | 2.9 |
| Guardian Pharmacy Services Inc ClaGRDN | $2.58B | 39.5 | 29.8 | 1.8 |
| Viridian Therapeutics OrsVRDN | $2.54B | — | — | 35.8 |
| Adma BiologicsADMA | $2.65B | 16.3 | 13.1 | 5.2 |
| AxogenAXGN | $2.65B | — | 73.6 | 9.9 |
| Mbx BiosciencesMBX | $2.66B | — | — | — |
| Brookdale Senior LivingBKD | $2.48B | — | — | 0.8 |
| PrecigenPGEN | $2.47B | — | 16.6 | 28.9 |
| Enliven TherapeuticsELVN | $2.69B | — | — | — |
| Peer median | 27.9 | 23.2 | 7.6 |
Reading these multiples
The P/E divides the share price by earnings per share over the last twelve months; the forward P/E divides it by the earnings analysts expect over the next twelve. Price to sales compares the company's market value with its revenue over the last twelve months. A multiple reads differently from one industry to the next, so the peer group above is the fairer comparison.
See also: NEOG financials · NEOG returns
No forecast, no recommendation. This page describes Neogen Corp from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.